23andMe Investor Presentation Deck

(in $M, except percentages) Therapeutics Research and Development Expense Consumer and Research Services Total R&D Expense Amount $66 73 $139 Nine Months Ended December 31, FY2022 Percentage of total R&D expense 47% 53% Amount $49 65 $114 FY2021 Percentage of total R&D expense 43% 57% YoY Copyright © 2022 23and Me, Inc. % Change 34% KK 12% Investing in Therapeutics <<< 23andMe 55

View entire presentation